Andover, Mass.-based TransMedics developed a transportation system for organ transplants that’s designed to keep donated hearts, lungs and livers in near-living condition until transplantation. A year ago it won pre-market approval from the FDA for its OCS Lung transplant device for standard double-lung transplantation procedures; in Europe, the OCS Heart and OCS Lung devices are already on the market.
Last week the company floated nearly 5.7 million shares at $16 each, for gross proceeds of $91.0 million. The IPO included an underwriters option for another 854,000 shares, which was exercised in full, for gross proceeds of $104.7 million, TransMedics said.
Morgan Stanley and J.P. Morgan were joint book-runners on the deal, with Cowen and Canaccord Genuity as co-managers.
TMDX shares, which closed up 10.5% yesterday at $27.41 apiece, were up another 6.9% to $26.50 each today in pre-market trading.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.